Drug–Drug Interactions with Sodium-Glucose Cotransporters Type 2 (SGLT2) Inhibitors, New Oral Glucose-Lowering Agents for the Management of Type 2 Diabetes Mellitus

Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor

(2014) André J. Scheen   CLINICAL PHARMACOKINETICS

Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations

(2014) André J Scheen   Expert Opinion on Drug Metabolism & Toxicology

Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations

(2013) Wendy L. Bennett et al.   ANNALS OF INTERNAL MEDICINE

Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes

(2013) Despoina Vasilakou et al.   ANNALS OF INTERNAL MEDICINE

Effect of Empagliflozin on the Steady-State Pharmacokinetics of Ethinylestradiol and Levonorgestrel in Healthy Female Volunteers

(2013) Sreeraj Macha et al.   CLINICAL DRUG INVESTIGATION

Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2

(2013) Sreeneeranj Kasichayanula et al.   CLINICAL PHARMACOKINETICS

A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetics of Empagliflozin and Linagliptin After Coadministration in Healthy Male Volunteers

(2013) Christian Friedrich et al.   CLINICAL THERAPEUTICS

Lack of Clinically Relevant Drug–Drug Interaction Between Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, and Verapamil, Ramipril, or Digoxin in Healthy Volunteers

(2013) Sreeraj Macha et al.   CLINICAL THERAPEUTICS

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

(2013) J.-F. Yale et al.   DIABETES OBESITY & METABOLISM

Canagliflozin: First Global Approval

(2013) Shelley Elkinson et al.   DRUGS

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

(2013)   EUROPEAN HEART JOURNAL

Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease

(2013) André J Scheen   Expert Opinion on Drug Metabolism & Toxicology

Canagliflozin, an inhibitor of sodium–glucose cotransporter 2, for the treatment of type 2 diabetes mellitus

(2013) Elizabeth M Lamos et al.   Expert Opinion on Drug Metabolism & Toxicology

Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes Mellitus

(2013) Damayanthi Devineni et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Impact of Voglibose on the Pharmacokinetics of Dapagliflozin in Japanese Patients with Type 2 Diabetes

(2013) Akira Imamura et al.   Diabetes Therapy

Pharmacokinetics of Empagliflozin, a Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitor, Coadministered with Sitagliptin in Healthy Volunteers

(2012) Tobias Brand et al.   ADVANCES IN THERAPY

Lack of Pharmacokinetic Interactions Between Dapagliflozin and Simvastatin, Valsartan, Warfarin, or Digoxin

(2012) Sreeneeranj Kasichayanula et al.   ADVANCES IN THERAPY

Drug-Drug Interactions with Glucagon-Like Peptide-1 Receptor Agonists

(2012) Kathryn M Hurren et al.   ANNALS OF PHARMACOTHERAPY

The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus

(2012) Sreeneeranj Kasichayanula et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers

(2012) S. Macha et al.   DIABETES OBESITY & METABOLISM

Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin

(2012) S. Kasichayanula et al.   DIABETES OBESITY & METABOLISM

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETOLOGIA

Dapagliflozin

(2012) Greg L. Plosker   DRUGS

Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers

(2012) Sreeraj Macha et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) in clinical practice in patients with vascular diseases or type 2 diabetes mellitus

(2012) Melvin Lafeber et al.   European Journal of Preventive Cardiology

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial

(2011) K. Strojek et al.   DIABETES OBESITY & METABOLISM

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

(2011) R. Grempler et al.   DIABETES OBESITY & METABOLISM

Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes

(2011) Muhammad A. Abdul-Ghani et al.   ENDOCRINE REVIEWS

Cytochrome P450-mediated cardiovascular drug interactions

(2011) André J Scheen   Expert Opinion on Drug Metabolism & Toxicology

Management of type 2 diabetes: new and future developments in treatment

(2011) Abd A Tahrani et al.   LANCET

Renal glucose reabsorption inhibitors to treat diabetes

(2011) Clifford J. Bailey   TRENDS IN PHARMACOLOGICAL SCIENCES

Dipeptidylpeptitase-4 Inhibitors (Gliptins)

(2010) André J. Scheen   CLINICAL PHARMACOKINETICS

Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects

(2010) S. Kasichayanula et al.   DIABETES OBESITY & METABOLISM

Reduction of the acute bioavailability of metformin by the α-glucosidase inhibitor acarbose in normal man

(2010) A. J. SCHEEN et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide

(2010) T. Tirkkonen et al.   JOURNAL OF INTERNAL MEDICINE